SG11201900815UA - Expression of pten-long with ocolytic viruses - Google Patents
Expression of pten-long with ocolytic virusesInfo
- Publication number
- SG11201900815UA SG11201900815UA SG11201900815UA SG11201900815UA SG11201900815UA SG 11201900815U A SG11201900815U A SG 11201900815UA SG 11201900815U A SG11201900815U A SG 11201900815UA SG 11201900815U A SG11201900815U A SG 11201900815UA SG 11201900815U A SG11201900815U A SG 11201900815UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- pten
- rule
- long
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368822P | 2016-07-29 | 2016-07-29 | |
| US201762479671P | 2017-03-31 | 2017-03-31 | |
| PCT/US2017/044683 WO2018023114A1 (en) | 2016-07-29 | 2017-07-31 | Expression of pten-long with ocolytic viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900815UA true SG11201900815UA (en) | 2019-02-27 |
Family
ID=61016870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900815UA SG11201900815UA (en) | 2016-07-29 | 2017-07-31 | Expression of pten-long with ocolytic viruses |
Country Status (10)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| AU2018316256B2 (en) * | 2017-08-09 | 2024-09-12 | Ohio State Innovation Foundation | Oncolytic virus carrying E-cadherin and uses thereof |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| CN108484780A (zh) * | 2018-04-16 | 2018-09-04 | 河南大学 | 一种融合蛋白PTEN-L-p53及其应用 |
| JP2022528203A (ja) | 2019-04-12 | 2022-06-08 | セラプテン バイオサイエンス インコーポレイテッド | 腫瘍抑制因子融合物の組成物およびその製造方法 |
| EP4010462A1 (en) * | 2019-08-05 | 2022-06-15 | Mesoblast International Sàrl | Cellular compositions comprising viral vectors and methods of treatment |
| CN111763260B (zh) * | 2020-06-11 | 2022-03-29 | 四川大学华西医院 | 一种PTEN-Long多克隆抗体及其制备方法和用途 |
| WO2024163335A2 (en) * | 2023-01-30 | 2024-08-08 | The Board Of Regents Of The University Of Texas System | Pten gene therapy vectors and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1601438A (enrdf_load_stackoverflow) | 1968-10-17 | 1970-08-24 | ||
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US6261834B1 (en) | 1991-11-08 | 2001-07-17 | Research Corporation Technologies, Inc. | Vector for gene therapy |
| GB9801930D0 (en) * | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| WO2005086922A2 (en) * | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| US20080292592A1 (en) * | 2004-04-30 | 2008-11-27 | Sunil Chada | Oncolytic Adenovirus Armed with Therapeutic Genes |
| KR20070111542A (ko) * | 2005-03-09 | 2007-11-21 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 암 치료유전자의 종양-특이적, 발현 고효율을 위한 신규한ｈＴＭＣ 프로모터 및 벡터 |
| AU2010216370A1 (en) * | 2009-02-17 | 2011-09-22 | The Trustees Of Columbia University In The City Of New York | Identification of extracellular form of PTEN that can be used to treat tumors |
| WO2011103339A1 (en) | 2010-02-17 | 2011-08-25 | The Trustees Of Columbia University In The City Of New York | Use of pten-long leader sequence for transmembrane delivery of molecules |
| KR101497035B1 (ko) * | 2010-04-26 | 2015-02-27 | 주식회사 녹십자 | 종양 특이적 프로모터 및 이를 포함하는 종양살상 바이러스 벡터 |
| EP2494978A1 (en) * | 2011-03-03 | 2012-09-05 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses |
| WO2013169388A1 (en) * | 2012-05-08 | 2013-11-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Predictive biomarkers for ctla-4 blockade therapy and for pd-1 blockade therapy |
| CN105209617B (zh) | 2013-03-13 | 2018-10-16 | 李忠 | 微囊泡及其制造方法 |
| AU2014342465B2 (en) * | 2013-10-28 | 2018-03-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic HSV vector |
| GB201408297D0 (en) * | 2014-05-12 | 2014-06-25 | Virttu Biolog Ltd | Treatment of cancer |
-
2017
- 2017-07-31 EP EP24176375.4A patent/EP4403229A3/en active Pending
- 2017-07-31 CA CA3032412A patent/CA3032412A1/en active Pending
- 2017-07-31 CN CN201780059869.5A patent/CN110087662A/zh active Pending
- 2017-07-31 US US16/321,777 patent/US20200085890A1/en active Pending
- 2017-07-31 BR BR112019001737-2A patent/BR112019001737A2/pt active Search and Examination
- 2017-07-31 JP JP2019504923A patent/JP7638061B2/ja active Active
- 2017-07-31 EP EP17835414.8A patent/EP3490574B8/en active Active
- 2017-07-31 SG SG11201900815UA patent/SG11201900815UA/en unknown
- 2017-07-31 KR KR1020197005487A patent/KR102780496B1/ko active Active
- 2017-07-31 AU AU2017301901A patent/AU2017301901B2/en active Active
- 2017-07-31 WO PCT/US2017/044683 patent/WO2018023114A1/en unknown
-
2022
- 2022-08-12 JP JP2022129037A patent/JP2022163182A/ja active Pending
-
2023
- 2023-01-06 US US18/151,195 patent/US20230338443A1/en active Pending
-
2024
- 2024-06-13 JP JP2024096293A patent/JP2024123088A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4403229A2 (en) | 2024-07-24 |
| WO2018023114A1 (en) | 2018-02-01 |
| CN110087662A (zh) | 2019-08-02 |
| KR20190035782A (ko) | 2019-04-03 |
| JP2022163182A (ja) | 2022-10-25 |
| AU2017301901B2 (en) | 2024-08-29 |
| EP3490574B1 (en) | 2024-05-22 |
| KR102780496B1 (ko) | 2025-03-11 |
| EP4403229A3 (en) | 2024-08-14 |
| US20200085890A1 (en) | 2020-03-19 |
| AU2017301901A1 (en) | 2019-02-21 |
| JP2024123088A (ja) | 2024-09-10 |
| EP3490574B8 (en) | 2024-07-10 |
| CA3032412A1 (en) | 2018-02-01 |
| US20230338443A1 (en) | 2023-10-26 |
| JP2019523008A (ja) | 2019-08-22 |
| JP7638061B2 (ja) | 2025-03-03 |
| EP3490574A1 (en) | 2019-06-05 |
| BR112019001737A2 (pt) | 2019-05-07 |
| EP3490574A4 (en) | 2020-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900815UA (en) | Expression of pten-long with ocolytic viruses | |
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201809993VA (en) | Oncolytic viruses comprising esrage and methods of treating cancer | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201907278VA (en) | Anti-tigit antibodies | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201906161VA (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201908012SA (en) | Cyclic sulfamide compounds and methods of using same | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF |